关于停药的相关内容

摘要：这3名患者在取得稳定的分子学缓解之后（融合基因转阴PCRU）停用达沙替尼。1名患者复发，另外两名患者在1年后仍保持了PCRU。以前说过，达沙替尼确实可以提高免疫力，希望今后能获得更多的相关研究报告。
  i8 @9 Z' s" k  \+ t& P    关于这个研究值得注意的是，这三名患者都是服用格列卫失败后转用达沙替尼的，也即他们对格列卫是耐药的。这与法国的格列卫停药研究又有所不同，那个研究中的患者都是对格列卫反应良好的。希望医生们能扩大研究长期观察，看看停用达沙替尼是否能持久不复发。
: y; g, ^4 w3 t7 Z1 I* {
作者：来自澳大利亚
1 D, s4 n4 v! r来源：Haematologica. 2011.8.9.
) M" c, o1 L) G/ zDear Group,

3 z2 m6 a; ?& E3 t5 a( h9 OSome of you are on Dasatinib (Sprycel) and we wish to give news on all CML
8 A. P/ v1 l, ~/ l. J; Qtherapies. Here is a report from Australia on 3 patients who went off Sprycel
after stable molecular response (PCRU). 1 patient relapsed but 2/3 patients
5 n! {1 A. {+ Aremain in stable PCRU at the 1 year mark. Some of you may remember that Sprycel
+ v+ {+ I$ B5 x# h4 e" bdoes spike up the immune system so I hope more reports come out on this issue.

The remarkable news about Sprycel cessation is that all 3 patients had failed
Gleevec and Sprycel was their second TKI so they had resistant disease. This is
0 ^5 b% ~0 ?- o* tdifferent from the stopping Gleevec trial in France which only targets patients
who have done well on Gleevec.
+ J* v/ [+ _( i, R
4 `1 v" \# M4 i/ v2 Z5 sHopefully, the doctors will report on a larger study and long-term to see if the
+ t) k+ i( g7 \5 K% V6 rresponse off Sprycel is sustained.
# T0 H  g5 W- J0 f* A- |
3 C9 N2 {6 C8 l+ ^% }* I% ^) }, \Best Wishes,
Anjana

# P, D- t& y4 _- D/ e

' A6 |) T; g) i! K1 M, nHaematologica. 2011 Aug 9. [Epub ahead of print]
0 B9 J, J+ l. Y% D, TDurable complete molecular remission of chronic myeloid leukemia following
dasatinib cessation, despite adverse disease features.
6 J! b  a6 x( t+ W0 VRoss DM, Bartley PA, Goyne J, Morley AA, Seymour JF, Grigg AP.
7 n$ ?/ ]' B; S, ~- ~5 u8 k+ @3 ~Source
Adelaide, Australia;

8 S/ V( w2 l, p. aAbstract
9 f% g8 L* e5 RPatients with chronic myeloid leukemia, treated with imatinib, who have a
durable complete molecular response might remain in CMR after stopping
treatment. Previous reports of patients stopping treatment in complete molecular
- Q4 O6 M( \" X+ Mresponse have included only patients with a good response to imatinib. We
describe three patients with stable complete molecular response on dasatinib
, E* }6 m% r+ v/ Y: K7 M8 V5 Streatment following imatinib failure. Two of the three patients remain in
8 `  F# b& M9 U0 t, C2 gcomplete molecular response more than 12 months after stopping dasatinib. In
these two patients we used highly sensitive patient-specific BCR-ABL1 DNA PCR to
. H6 j. n) Z: h# Q0 b% g9 s. u! Sshow that the leukemic clone remains detectable, as we have previously shown in
. `8 n7 ?# w# S/ oimatinib-treated patients. Dasatinib-associated immunological phenomena, such as
9 q1 a( [" t8 a0 `8 p2 e6 b* Q# f0 bthe emergence of clonal T cell populations, were observed both in one patient
$ g3 i4 }! R5 G( dwho relapsed and in one patient in remission. Our results suggest that the
characteristics of complete molecular response on dasatinib treatment may be
2 b, c- l# e. z% h* N4 c0 h) Y# ~similar to that achieved with imatinib, at least in patients with adverse
disease features.

摘要：（STIM试验为法国的格列卫停药试验。）这个研究中，患者先是取得了CMR（融合基因转阴），然后停用格列卫，而后复发。15名复发患者在重新服药后又一次取得了CMR，他们同意再次停药。
    第一次CMR持续时间为31个月，然后患者停药，复发的中位时间为2.6个月，然后重新服用格列卫，中位时间5.3个月之后取得第二次CMR。保持第二次CMR中位时间19个月之后，患者同意再次停药，这次，15名患者中有5名在停药随访中位时间24个月后仍然保持了CMR，而10名患者在停药中位时间2月后第二次复发。
3 F; y. f6 w$ O5 O0 S. O    请注意，这些患者都是在第一次CMR后停药然后又复发的患者。
; Y; t3 S* g7 f& a- _8 U) n
- R3 b/ }1 I; X6 Y作者：来自法国STIM试验
来源：EHA 2011.6.会议摘要

很不错的文章，看来马老师家有考虑停药的想法了啊！祝福！

期盼易或特也能停药，但现在觉得是一个梦想！

这个非常有意义的研究。能吃下来停会再吃，再停，那是天大的好事